BCAB Projected Dividend Yield
BioAtla Inc ( NASDAQ : BCAB )BioAtla is a clinical-stage biopharmaceutical company developing its antibody-based therapeutics for the treatment of solid tumor cancer. Co.'s conditionally active biologics (CAB) capitalize on its proprietary discoveries with respect to tumor biology, enabling Co. to target known and validated tumor antigens. Co.'s CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. Unlike healthy tissue, the tumor microenvironment is acidic and has designed its antibodies to selectively bind to their targets on cancer cells under acidic pH conditions but not on targets in normal tissues. 20 YEAR PERFORMANCE RESULTS |
BCAB Dividend History Detail BCAB Dividend News BCAB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |